Skip to main content
GERN logo

GERN

Geron Corp
$1.49 +0.05 (+3.47%) At close · Jul 7
Market Cap
$955.87M
Shares
641,520,974

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.49 Open$1.44 Day$1.41–1.50 52W$1.04–2.01 Avg vol 30d13.1M Short int74.8M · 11.7% float · 5.9d Short vol51% Last earningsMay 6, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 6
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +7%
above
Price vs 50-day avg +12%
above
RSI (14) 68
neutral
MACD trend Positive
52-week position 46%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +27%
trailing
6-month return +4%
trailing
YTD return +13%
this year
Relative strength −3%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
8 of 255 funds reported for Jun 30 · net +654.9K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.67% of float · ▲ +4.3% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
255 holders — mid 3-yr range
Squeeze score 82
high risk · 0–100
Fundamentals
Fair
Revenue growth −83%
Y/Y
EPS growth +52%
Y/Y
Free cash flow $-111.7M
Balance sheet $77.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −44%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
Next earnings call
Aug 5, 2026 Est · unconfirmed · in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 6, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Guidance & track record
      Latest guidance · from the Earnings Call filed Mar 31, 2026
      Net revenue · 2026 Initiated $220M – $240M
      Total operating expenses · 2026 Initiated $230M – $240M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +7% Bullish
      Price vs 50-day avg
      +12% Bullish
      RSI (14)
      68 Neutral
      MACD trend
      Positive Bullish
      52-week position
      46% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $1 — 200d above 50d
      Institutional flow Accumulating
      8 of 255 funds reported for Jun 30 · net +654.9K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      11.67% of float · ▲ +4.3% MoM · 5.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      255 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $1 Now $1 · 46% 52-wk high $2
      vs 200-day avg +7% vs 50-day avg +12%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      demand growth quarter-over-quarter 6% Q1 2026 call
      estimated second-line lower-risk MDS patients in the U.S. 8,000 Q1 2026 call
      first and second-line patient starts rolling 12-month basis 33% rolling 12-month basis as of Q1 2026 call
      gross-to-net reductions 21% Q1 2026 call
      prescribing accounts since launch 1,450 since launch to Q1 2026 call

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      GERN
      Geron Corp
      this stock
      $955.87M +12.9% -82.7% 11.7%
      ONC
      BeOne Medicines Ltd.
      $446.53B +1.7% +22179.2% 908.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $132.55B +15.2% +46.2% 31.0 1.8%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $70.90B -12.3% +20.8% 16.5 3.2%
      ARGX
      Argenx SE
      $57.20B +8.8% 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      255
      % held
      77.2%
      Reported
      8 of 255
      Top holder
      RA CAPITAL MANAGEMENT, L.…
      Held Float
      View
      Held by Funds
      Fund positions
      123
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      74.8M
      Days to cover
      5.9d
      Change
      +3.1M sh
      View
      Short Volume
      Short vol %
      51%
      As of
      Jul 8, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      145.8K
      Value
      $170.6K
      As of
      Jun 8, 2026
      View
      Off-Exchange
      Off-exchange %
      61.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $237.0K
      Net income (FY)
      $-83.5M
      EPS diluted
      $-0.13
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $27.4K
      Shares
      20.0K
      Filed
      Dec 15, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 8, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      GERN +14.6% +27.4% +4.2% +16.4% +12.9%
      SPY +0.9% +1.4% +7.6% +0.1% +9.7%
      vs SPY +13.7% +26.0% -3.4% +16.3% +3.2%
      Key facts CIK 886744 CUSIP 374163103 13F (30d) 9 filings 8 filers Visit website Investor relations